Skip to content

AXIM BIOTECHNOLOGIES, INC.: 10-Q filed 2021-11-22

What AXIM BIOTECHNOLOGIES, INC. reported in its quarterly report filed 2021-11-22 (fiscal Q3 2021): 39 published measures, 116 facts as tagged in accession 0001096906-21-002816.

This filing

Form
10-Q (quarterly report)
Filed
2021-11-22
Fiscal period
fiscal Q3 2021
Accession
0001096906-21-002816 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AXIM BIOTECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-09-3014,247,964USD
At 2020-12-3111,314,395USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-09-309,600,293USD
At 2020-12-319,748,574USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-09-304,647,671USD
At 2021-06-301,037,600USD
At 2021-03-311,628,528USD
At 2020-12-311,565,821USD
At 2020-09-302,287,497USD
At 2020-06-30999,105USD
At 2020-03-31-361,712USD
At 2019-12-31-6,760,397USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-09-30338,377USD
At 2020-12-31457,181USD
At 2020-09-301,157,239USD
At 2019-12-31511,630USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-3,291,677USD92
2021-01-01 to 2021-09-30-7,983,134USD273
2021-04-01 to 2021-06-30-3,826,924USD91
2021-01-01 to 2021-03-31-864,536USD90
2020-07-01 to 2020-09-30-1,905,567USD92
2020-01-01 to 2020-09-30-4,013,324USD274
2020-04-01 to 2020-06-30-79,389USD91
2020-01-01 to 2020-03-31-2,028,367USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-1,693,833USD273
2020-01-01 to 2020-09-30-2,600,784USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2021-07-01 to 2021-09-308,127USD92
2021-01-01 to 2021-09-3055,651USD273
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-09-301,605,051USD273
2020-01-01 to 2020-09-303,252,748USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-30,022USD273
2020-01-01 to 2020-09-30-6,355USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-09-30-49,833,059USD
At 2020-12-31-41,849,922USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-0.02USD/shares92
2021-01-01 to 2021-09-30-0.06USD/shares273
2020-07-01 to 2020-09-30-0.02USD/shares92
2020-01-01 to 2020-09-30-0.04USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-0.02USD/shares92
2021-01-01 to 2021-09-30-0.06USD/shares273
2020-07-01 to 2020-09-30-0.02USD/shares92
2020-01-01 to 2020-09-30-0.04USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-07-01 to 2021-09-300USD92
2021-01-01 to 2021-09-300USD273
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-09-30103,997USD
At 2020-12-31104,094USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-09-30953,076USD273
2020-01-01 to 2020-09-30779,029USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-3,278,456USD92
2021-01-01 to 2021-09-30-6,327,494USD273
2020-07-01 to 2020-09-30-1,298,778USD92
2020-01-01 to 2020-09-30-2,688,348USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-09-30500,046USD
At 2020-12-31713,104USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2021-07-01 to 2021-09-300USD92
2021-01-01 to 2021-09-300USD273
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-09-301,594,859USD
At 2020-12-311,496,267USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2021-09-302,458,233USD
At 2020-12-312,458,233USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-07-01 to 2021-09-303,286,583USD92
2021-01-01 to 2021-09-306,383,145USD273
2020-07-01 to 2020-09-301,298,778USD92
2020-01-01 to 2020-09-302,688,348USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-09-3020,127USD
At 2020-12-310USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2021-07-01 to 2021-09-302,519,527USD92
2021-01-01 to 2021-09-304,812,790USD273
2020-07-01 to 2020-09-301,184,267USD92
2020-01-01 to 2020-09-302,442,420USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-07-01 to 2021-09-3067,263USD92
2021-01-01 to 2021-09-30216,282USD273
2020-07-01 to 2020-09-30109,139USD92
2020-01-01 to 2020-09-30235,431USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-09-30135,885,104shares
At 2020-12-31125,327,579shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-09-3050,009,591USD
At 2020-12-3143,201,186USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-09-3090,630USD
At 2020-12-31130,722USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-09-30154,809USD
At 2020-12-31134,788USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-09-3050,812USD
At 2020-12-3130,694USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2021-09-306,503,562USD
At 2020-12-317,800,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2021-09-301,445USD
At 2020-12-31675USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2021-09-302,340,000USD
At 2020-12-312,340,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-3,291,677USD92
2021-01-01 to 2021-09-30-7,978,501USD273
2020-07-01 to 2020-09-30-2,291,804USD92
2020-01-01 to 2020-09-30-4,042,468USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-7,983,134USD273
2020-01-01 to 2020-09-30-4,013,324USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-07-01 to 2021-09-306,935USD92
2021-01-01 to 2021-09-3020,119USD273
2020-07-01 to 2020-09-305,372USD92
2020-01-01 to 2020-09-3010,497USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-07-01 to 2021-09-3013,221USD92
2021-01-01 to 2021-09-301,651,007USD273
2020-07-01 to 2020-09-30993,026USD92
2020-01-01 to 2020-09-301,354,120USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-01-01 to 2021-09-300USD273
2020-01-01 to 2020-09-300USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2021-01-01 to 2021-09-300USD273
2020-01-01 to 2020-09-300USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-20,127USD273
2020-01-01 to 2020-09-300USD274

Inspect the source

Entity
AXIM BIOTECHNOLOGIES, INC. / CIK 0001514946
Captured
2026-09-20T09:13:30.666Z
SEC response SHA-256
5755093e2dfb1c20119737eacb251a5ef040e09cdc537c89d6edf9272249749e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514946.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))